These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22114888)

  • 1. Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
    Patrignani P; Tacconelli S; Bruno A; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):605-21. PubMed ID: 22114888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
    Konishi H; Yoshikawa T
    Nihon Rinsho; 2011 Jun; 69(6):1110-5. PubMed ID: 21688637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.
    Lanas A; Tornero J; Zamorano JL
    Ann Rheum Dis; 2010 Aug; 69(8):1453-8. PubMed ID: 20498210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.
    Scarpignato C; Hunt RH
    Gastroenterol Clin North Am; 2010 Sep; 39(3):433-64. PubMed ID: 20951911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NSAID dilemma: managing osteoarthritis in high-risk patients.
    Roth SH; Anderson S
    Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
    Fries JF; Bruce B
    J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.